Evaluation of the Entresto Effect on Sympathic Nervous System in Patient With Heart Failure

Summary

The hyperactivation of the sympathetic nervous system is a feature of the heart failure and the determinants of disease progression and risk of sudden cardiac death. This research project aims to study, in the drug use conditions provided in the summary of product characteristics based on European marketing authorization (indications and dosage), the effect of the Entresto® on the activity of sympathic nervous system using the reference method, the microneurographic recording of sympathetic activity in muscle destiny (MSNA). This study will try to determine if the double inhibition of AT1 receptor and neprilysin activity result in lower sympathic nervous system burst rate versus single AT1 receptor inhibition using angiotensin-converting-enzyme inhibitor or AT1 receptor of angiotensin II inhibitor.

Timeline

Start

2016-10

Primary completion

2018-01

Completion

2018-01

Outcome

Outcome not reported

Stopped: “Today Entresto treatment has marketing authorization and is available for all patients, that is the reason why study was halted prematurely.”

Drugs

Indications